AU2011348396A1 - OprF/I agents and their use in hospitalized and other patients - Google Patents

OprF/I agents and their use in hospitalized and other patients Download PDF

Info

Publication number
AU2011348396A1
AU2011348396A1 AU2011348396A AU2011348396A AU2011348396A1 AU 2011348396 A1 AU2011348396 A1 AU 2011348396A1 AU 2011348396 A AU2011348396 A AU 2011348396A AU 2011348396 A AU2011348396 A AU 2011348396A AU 2011348396 A1 AU2011348396 A1 AU 2011348396A1
Authority
AU
Australia
Prior art keywords
oprf
seq
agent
bond
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011348396A
Other languages
English (en)
Other versions
AU2011348396A2 (en
Inventor
Christoph Klade
Robert Schlegl
Kerstin Westritschnig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of AU2011348396A1 publication Critical patent/AU2011348396A1/en
Publication of AU2011348396A2 publication Critical patent/AU2011348396A2/en
Assigned to VALNEVA AUSTRIA GMBH reassignment VALNEVA AUSTRIA GMBH Amend patent request/document other than specification (104) Assignors: INTERCELL AUSTRIA AG
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011348396A 2010-12-23 2011-03-18 OprF/I agents and their use in hospitalized and other patients Abandoned AU2011348396A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
US61/426,760 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Publications (2)

Publication Number Publication Date
AU2011348396A1 true AU2011348396A1 (en) 2013-07-04
AU2011348396A2 AU2011348396A2 (en) 2013-07-11

Family

ID=44210049

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011348396A Abandoned AU2011348396A1 (en) 2010-12-23 2011-03-18 OprF/I agents and their use in hospitalized and other patients

Country Status (11)

Country Link
US (1) US20130266575A1 (https=)
EP (1) EP2655402A1 (https=)
JP (2) JP5893640B2 (https=)
KR (1) KR20130133212A (https=)
CN (1) CN103270047A (https=)
AU (1) AU2011348396A1 (https=)
BR (1) BR112013016254A2 (https=)
CA (1) CA2822684A1 (https=)
MX (1) MX2013007146A (https=)
WO (1) WO2012084272A1 (https=)
ZA (1) ZA201304235B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111249455A (zh) 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
EA201790489A1 (ru) 2014-08-29 2017-08-31 Сорренто Терапьютикс, Инк. ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА НА ОСНОВЕ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ OprF И OprI
ES2846881T3 (es) 2015-05-01 2021-07-30 Inhibrx Inc Moléculas que se dirigen al sistema de secreción de tipo III
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
CA2991634C (en) 2015-07-16 2026-03-17 Inhibrx Biosciences, Inc. Multivalent and multispecific dr5-binding fusion proteins
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
ATE190657T1 (de) * 1994-12-16 2000-04-15 Chiron Behring Gmbh & Co Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
JP2005501889A (ja) * 2001-09-03 2005-01-20 アンビクス パテンツ−ライセンシーズ アーゲー マクロライド系抗生物質を用いる緑膿菌感染症の治療法
AU2002340683C1 (en) * 2001-11-13 2009-11-12 Id Biomedical Corporation Of Quebec Polypeptides of pseudomonas aeruginosa
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
EP1861110B1 (en) * 2004-12-17 2014-03-26 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
CN111249455A (zh) * 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合

Also Published As

Publication number Publication date
JP2014504297A (ja) 2014-02-20
CA2822684A1 (en) 2012-06-28
JP5893640B2 (ja) 2016-03-23
KR20130133212A (ko) 2013-12-06
WO2012084272A1 (en) 2012-06-28
ZA201304235B (en) 2014-09-25
BR112013016254A2 (pt) 2017-07-11
US20130266575A1 (en) 2013-10-10
JP2016147867A (ja) 2016-08-18
CN103270047A (zh) 2013-08-28
MX2013007146A (es) 2013-11-01
AU2011348396A2 (en) 2013-07-11
EP2655402A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
US20130266575A1 (en) OprF/I AGENTS AND USE THEREOF IN HOSPITALIZED AND OTHER PATIENTS
CN111690059B (zh) 一种抗SARS-CoV-2的单克隆抗体1D7
JP6048845B2 (ja) ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
AU2014259474B2 (en) Stabilized soluble prefusion RSV F polypeptides
CN112521494B (zh) 一种抗SARS-CoV-2的单克隆抗体2B11
CN111732654B (zh) 一种抗SARS-CoV-2的单克隆抗体1E10
US12227545B2 (en) Acinetobacter baumannii immunogenic protein and composition and application thereof
EP4119154A1 (en) Influenza virus vaccines and uses thereof
KR102094569B1 (ko) 돼지의 부종병을 예방하는 백신
Burkhardt et al. Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A
US20160362480A1 (en) Novel oprf/i fusion proteins, their preparation and use
CN105542003B (zh) 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
HK1188799A (en) Oprf/i agents and their use in hospitalized and other patients
CN120771269A (zh) 源于细菌表面受体蛋白的免疫原性组合物和疫苗
CN113817051B (zh) 一种抗SARS-CoV-2的单克隆抗体1B6
EP3554639A1 (en) Novel recombinant protein uk 114 in stable polymer form for use in the treatment, diagnosis and prevention of malignant solid and systemic tumours
TWI759750B (zh) 一種以重組毒素製作抗蛇毒血清方法
CN113817050A (zh) 一种抗SARS-CoV-2的单克隆抗体1H8
Sudarkina et al. Production and characterization of the B chains of mistletoe toxic lectins
CN116270998A (zh) 基于双受体结合区rbd组装的多价生物毒素抗原疫苗及其制备方法与应用
CN110938150A (zh) E型肉毒毒素重组hn-l抗原的制备方法及其应用
HK1229841A1 (zh) 源於细菌表面受体蛋白的免疫原性组合物和疫苗

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JUN 2013

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted